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lead placed between the breast and the table. Thus, during 
the treatment, the breast rested over this lead shield. In 
addition, two lateral pieces of lead (3 cm thick each) were 
added. One of the lateral layers had a port through which the 
transfer tubes were connected to the catheters. The lateral 
blocks allowed placing an extra piece of lead (2.5 cm thick) 
above the breast, parallel to the first layer, aiming to reduce 
primary radiation to the thyroids and eye lenses. In addition, 
in order to minimize the transit dose when the 192Ir source 
exits and returns to the remote afterloader, a hollow lead 
tube was made, which covered the transfer tubes. Finally, a 
layer of water-equivalent material (1 mm thick) was placed 
between the lead shielding and the patient skin to minimize 
the backscattering and electron contamination coming from 
the shield. Radiochromic films and thermoluminescent 
dosimeters were placed between the slices of an 
anthropomorphic phantom modeling the patient. Dose 
variation as a function of distance from the implant volume 
as well as dose homogeneity within a representative slice of 
the fetal position was evaluated without and with shielding. 
 
 
Results: When using the shielding, the peripheral dose 
decreased exponentially with the distance, and ranged from 
50 cGy at 5 cm from the caudal edge of the breast to < 0.1 
cGy at 30 cm. The shielding reduces absorbed dose by a 
factor of two near the breast and more than an order of 
magnitude beyond 20 cm. The dose is heterogeneous within a 
given patient axial plane, with measured variations from the 
central region within 50%. The fetal dose evaluated in this 
study with the designed lead shielding was compared with 
reported doses to the fetus from external-beam radiotherapy 
(EBRT) applied to the breast. Interstitial HDR 192Ir 
brachytherapy with breast shielding can be more 
advantageous than EBRT from a radiation protection point of 
view for pregnant patients, as long as the distance to the 
fundus is higher than 10 to 12 cm. Furthermore, the weight 
of the shielding here proposed (roughly 40 kg) is notably 
lower than the ones needed in EBRT (around 200 kg). 
Conclusions: Shielded HDR breast brachytherapy is a 
treatment option that may benefit pregnant patients needing 
localized radiotherapy, especially during the early gestational 
ages when the fetus is more sensitive to ionizing radiation.  
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Purpose/Objective: The purpose was to estimate the dose to 
the foetus in a case when a pregnant patient, 16 weeks after 
conception, were in need of stereotactic radiotherapy with 
6MV against head and lung. 
Materials and Methods: Four treatment plans, three for the 
brain metastasis and one for the lung metastasis, were 
available. The prescribed doses were 25 Gy x 1 fraction for 
the brain tumours and 15 Gy x 3 fractions for the lung. The 
photon energy spectrum in the position of foetus (about 32cm 
from lower field limit in the lung treatment) and the 
normalised dose (µGy/MU) in certain distances from the 
treatment volume were available from literature 1. Four 
different approaches for dose estimates were used: 1) based 
on measurements with ionisation chamber in an Alderson full 
body phantom, 2) tps data estimated from the scanned 
Alderson full body phantom (Oncentra v.4.3, Elekta), 3) 
measurements with TLD at the skin entrance during patient 
treatment and 4) based on literature. 
Results: In table 1 are the different plans and measurements 
with ionisation chamber summarized. The measurements in 
Alderson were in total 40mGy, 34 mGy from the plan in the 
lung and the remaining from the brain-plans. The tps 
calculated the dose in Alderson from the lung-plan to 53mGy. 
TLD measurements showed 30mGy (no energy correction) and 
from literature the estimated dose became 60mGy (4x4cm2 
fields). In total the foetus dose was estimated to 40±10 mGy. 
 
 
S872                                                                                                                                         3rd ESTRO Forum 2015 
 
Conclusions: The measurement in Alderson phantom is 
presumed to give most accurate estimate, even though the 
real patient dimensions may differ. For situations where the 
first estimates indicate doses >100 mSv it should be 
considered to do a low dose CT scan of the patient and 
transfer to the dose planning system. When the distance from 
uterus to lower field limit is less than 20cm the dose planning 
system seems to be quite accurate.  
Such cases need to be carefully considered by the clinical 
team in the hospital; the patient and family members need 
evidence based medical advises in this difficult ethical 
dilemma. In this case there was no indication for abortus 
provocatus due to the radiation dose itself. 
 
Reference: 
1. Kry SF, Titt U, Pönisch F, et.al. A Monte Carlo model for 
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Purpose/Objective: Oncoplastic surgery has become more 
frequent in the last few years, because of excellent cosmetic 
results. Adjuvant radiotherapy procedures have to cope with 
breast tissue displacements in the postoperative target 
definition. 
The purpose is to present our methodology for image guided 
HDR interstitial Brachytherapy of breast cancer, based on 
localize stereotactically the target volume and doing the 
implant image-guided to better fit its volume. 
Materials and Methods: 20 breast cancer patients (10 T1 and 
10 T2, median size 17.5mm) treated with post-operative 
image guided brachytherapy (IGBT), 19 were boost before 
external RT (18 cases 7Gy-1 session, and 1 case 5Gy-3 
sessions), and one was exclusive treatment (4Gy-8 sessions). 
Computed Tomography (CT) Phillips BrillianceTM, treatment 
planning systems (TPS) Pinnacle³ TM (external) and Elekta 
OncentraTM Brachy (brachytherapy), Linear Accelerator Varian 
Clinac TM 2100C/D, and HDR delivery system Elekta 
microSelectronTM with Elekta COMFORTTM Catheter Applicator 
System. 
The starting point was a CT with the patient in a favorable 
position for the catheter implantation and fixed using a 
vacuum cushion for head and shoulders. Using Pinnacle³ TM as 
a virtual simulator two opposite beams were defined, 
collimated to the PTV, and with gantry angles that satisfy 
(figure below): 
- Anatomically feasible geometry for the implant (possibility 
of covering the PTV without crossing with the needles the 
chest wall plus a 6mm margin) 
- Minimum PTV section and exposed skin area, with the least 
healthy tissue crossed by needles (minimizing the number of 
catheters) 
Also the length should be less than 20cm in every possible 
catheter path (maximum needle length). Depending on the 
BEV area, the number of catheters was decided. 
A set of representatives points for the BEV perimeter were 
chosen, and their 3D coordinates registered (relative to the 
point marked by tattoos in the CT). Using the Clinac as a 
simulator, all these couch displacements were made, and so 
all the points were marked on the skin. These marks were the 
guidance for the implant process (it enclosed the entrance & 
exit points). After the implant, a new CT was made to check 
the needle setting, allowing for corrections if there are PTV 
areas far from any needle (6mm). Finally, the treatment was 
planned with OncentraTM Brachy, 3D criteria, and graphical 
optimization. 
 
 
Results: The mean PTV size was 43.2cc and the mean number 
of catheters was 9. The dosimetric results were analyzed by 
some quality parameters: 
- For the PTV the D90, homogeneity (DHI=1- V150/V100), and 
conformity index (RTOG-CI). 
- For the OARs (skin and chest wall), the volume exposed at 
doses greater than 70% of the prescribed dose. 
 
Conclusions: We obtained good results for the CI and DHI 
parameters, keeping the V70% for OAR’s at clinically 
optimized levels. 
